Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VSTM

Verastem Inc

Nov 30 • 12:18PM ET

6.64

Dollar change +0.24
Percentage change 3.67	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.04	Insider Own	24.31%	Shs Outstand	25.27M	Perf Week	3.19%
Market Cap	167.67M	Forward P/E	-	EPS next Y	-3.01	Insider Trans	-0.06%	Shs Float	19.13M	Perf Month	5.65%
Income	-76.81M	PEG	-	EPS next Q	-0.64	Inst Own	48.70%	Short Float / Ratio	2.52% / 6.04	Perf Quarter	-32.02%
Sales	0.00M	P/S	-	EPS this Y	29.39%	Inst Trans	-	Short Interest	0.48M	Perf Half Y	-44.98%
Book/sh	3.29	P/B	2.02	EPS next Y	6.44%	ROA	-53.48%	Target Price	28.79	Perf Year	35.99%
Cash/sh	6.62	P/C	1.00	EPS next 5Y	1.74%	ROE	-91.87%	52W Range	3.87 - 15.18	Perf YTD	37.37%
Dividend	-	P/FCF	-	EPS past 5Y	26.40%	ROI	-50.43%	52W High	-56.29%	Beta	0.54
Dividend %	-	Quick Ratio	7.33	Sales past 5Y	-45.06%	Gross Margin	-	52W Low	71.45%	ATR	0.45
Employees	57	Current Ratio	7.33	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	48.80	Volatility	5.36% 7.05%
Optionable	Yes	Debt/Eq	0.47	EPS Q/Q	32.19%	Profit Margin	-	Rel Volume	1.28	Prev Close	6.40
Shortable	Yes	LT Debt/Eq	0.46	Earnings	Nov 08 AMC	Payout	-	Avg Volume	80.00K	Price	6.64
Recom	1.00	SMA20	2.29%	SMA50	-8.83%	SMA200	-12.29%	Volume	46,990	Change	3.67%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14
Mar-08-18	Initiated	B. Riley FBR, Inc.	Buy	$15
Sep-07-17	Reiterated	H.C. Wainwright	Buy	$6.50 → $10
Apr-13-17	Initiated	Oppenheimer	Outperform
Mar-24-17	Reiterated	H.C. Wainwright	Buy	$5 → $6.50
Sep-29-15	Downgrade	Raymond James	Strong Buy → Outperform
Sep-29-15	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-29-15	Downgrade	Jefferies	Buy → Hold

Show Previous Ratings

Nov-22-23 12:00PM	All You Need to Know About Verastem (VSTM) Rating Upgrade to Buy (Zacks)
Nov-13-23 07:00AM	New Healthcare Professional Component of Lets Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach (Business Wire)
Nov-08-23 05:52PM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
04:12PM	Verastem Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Nov-07-23 07:00AM	First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique Challenges and Gaps in Care for Patients with Low-Grade Serous Ovarian Cancer (Business Wire) +6.65%
07:00AM	Loading…
Nov-06-23 07:00AM	Verastem Oncology Announces Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population (Business Wire)
Oct-26-23 04:05PM	Verastem Oncology Strengthens Executive Leadership Team with Key Appointments (Business Wire)
Oct-18-23 04:50PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-14-23 12:30PM	Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS (sotorasib) in KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Oct-06-23 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-28-23 02:15PM	Verastem Presents Avutometinib and Defactinib Combination Program Updates at the 5th Annual RAS-Targeted Drug Development Summit (Business Wire) -5.13%
Sep-05-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Sep-04-23 01:23PM	3 Penny Stocks That Can Triple Your Money in the Next 12 Months (InvestorPlace)
Aug-28-23 07:00AM	Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting RAS Pathway-Driven Cancers (Business Wire)
Aug-08-23 05:46PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-11-23 07:00AM	Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer (Business Wire)
Jul-10-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +9.50%
Jul-05-23 04:05PM	Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jun-16-23 05:00AM	Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Jun-15-23 04:06PM	Verastem Stock Is Outperforming 92% Of The Market And It Just Surged (Investor's Business Daily) +16.09%
04:00PM	Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
May-31-23 09:11AM	Verastem Oncology Announces Reverse Stock Split (Business Wire)
May-25-23 05:05PM	Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib (Business Wire)
May-16-23 07:00AM	Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors (Business Wire)
May-09-23 04:56PM	Verastem: Q1 Earnings Snapshot (AP Finance)
04:05PM	Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (Business Wire)
May-02-23 07:45AM	Strong week for Verastem (NASDAQ:VSTM) shareholders doesn't alleviate pain of five-year loss (Simply Wall St.)
May-01-23 07:00AM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire) +12.65%
Apr-26-23 04:05PM	New Data from Interim Analysis of Verastem Oncologys RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting (Business Wire)
07:05AM	Loading…
Apr-18-23 07:05AM	Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days (Business Wire)
Apr-06-23 05:39PM	7 Very Undervalued Penny Stocks to Buy in April 2023 (InvestorPlace) -6.12%
04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-15-23 07:00AM	New Verastem Oncology Initiative, Lets Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer (Business Wire)
Mar-14-23 04:05PM	Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Feb-02-23 07:00AM	Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire) +8.65%
Jan-30-23 12:00PM	Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) -5.80%
Jan-24-23 05:46PM	Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock (Business Wire)
05:45PM	Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Jan-18-23 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-11-23 06:24AM	individual investors who own 37% along with institutions invested in Verastem, Inc. (NASDAQ:VSTM) saw increase in their holdings value last week (Simply Wall St.) +11.00%
Dec-15-22 04:30PM	Verastem Oncology Appoints Rob Gagnon to Board of Directors (Business Wire) -5.00%
Nov-08-22 08:22AM	Verastem Third Quarter 2022 Earnings: US$0.092 loss per share (vs US$0.13 loss in 3Q 2021) (Simply Wall St.)
Nov-03-22 04:05PM	Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire)
Oct-20-22 07:00AM	Verastem Oncology Appoints Anil Kapur to Board of Directors (Business Wire)
Oct-07-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.49%
Oct-04-22 07:00AM	Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates (Business Wire) -34.60%
Sep-19-22 09:31AM	10 Long-Term Stocks to Buy During Recessions (Insider Monkey)
Aug-23-22 12:23PM	Investors five-year losses grow to 64% as the stock sheds US$34m this past week (Simply Wall St.)
Aug-08-22 07:00AM	Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) +7.56%
Jul-27-22 11:40AM	Is Verastem (NASDAQ:VSTM) Using Too Much Debt? (Simply Wall St.)
Jul-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.93%
Jun-27-22 11:17AM	What You Need To Know About Verastem, Inc.'s (NASDAQ:VSTM) Investor Composition (Simply Wall St.)
Jun-07-22 02:26PM	RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm (Benzinga) +11.07%
Jun-06-22 07:00AM	Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer (Business Wire) -8.27%
May-19-22 06:00PM	7 Cheap Biotech Stocks to Buy Now (InvestorPlace) +5.13%
May-18-22 08:45AM	Verastem Oncology Awarded Pancreatic Cancer Action Networks First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer (Business Wire)
May-09-22 04:05PM	Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress (Business Wire) -9.52%
08:25AM	Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-04-22 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.99%
Mar-28-22 01:46PM	Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development (Benzinga) +10.92%
07:05AM	Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
07:00AM	Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors (Business Wire)
Mar-24-22 07:05AM	Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board (Business Wire)
Mar-01-22 07:52AM	Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates (Zacks)
Feb-22-22 05:00AM	Verastem (NASDAQ:VSTM) investors are sitting on a loss of 62% if they invested three years ago (Simply Wall St.)
Feb-03-22 05:38PM	Kalos Management, Inc. Buys Vale SA, Sells Consensus Cloud Solutions Inc, Intuitive Surgical ... (GuruFocus.com) -7.59%
Jan-11-22 07:00AM	Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers (Business Wire)
Jan-07-22 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-22 04:05PM	Verastem Oncology to Participate in Upcoming Investor Conferences (Business Wire)
Nov-23-21 08:53AM	Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC (Zacks)
Nov-22-21 07:30AM	Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer (PR Newswire)
Nov-15-21 06:01AM	10 Best Biotech Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey)
Nov-14-21 08:53AM	10 Best Biotech Stocks Under $5 (Insider Monkey)
Nov-11-21 07:00AM	Verastem Oncology to Present at the Jefferies London Healthcare Conference (Business Wire) +10.57%
Nov-04-21 04:05PM	Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
09:25AM	11 Best Long-Term Stocks To Buy Now (Insider Monkey)
Oct-26-21 07:00AM	Verastem Oncology Appoints Michelle Robertson to Board of Directors (Business Wire)
Oct-25-21 04:01PM	Hedge Funds Are Crazy About Verastem Inc (VSTM) (Insider Monkey)
Oct-20-21 10:52AM	Is Verastem, Inc. (NASDAQ:VSTM) Popular Amongst Institutions? (Simply Wall St.)
Sep-27-21 10:08AM	3 Biotech Stocks That Could Make You Filthy Rich (Motley Fool)
Sep-24-21 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-22-21 07:00AM	Verastem Oncology Appoints Louis J. Denis, M.D., as Chief Medical Officer (Business Wire)
Sep-20-21 03:49PM	Why Verastem Stock Spiked Today (Motley Fool)
12:07PM	Why Verastem Shares Are Trading Higher Today (Benzinga)
07:00AM	Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with KRAS G12C-Mutant Non-Small Cell Lung Cancer (Business Wire)
Sep-19-21 11:30AM	Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021 (Business Wire)
Sep-10-21 12:54PM	Investors in Verastem (NASDAQ:VSTM) have made a impressive return of 122% over the past year (Simply Wall St.)
Sep-07-21 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-05-21 09:06AM	Is Verastem (NASDAQ:VSTM) A Risky Investment? (Simply Wall St.)
Aug-02-21 04:05PM	Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress (Business Wire)
Jul-27-21 07:00AM	Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini Oral Presentation at the European Society of Medical Oncology Congress 2021 (Business Wire)
Jul-19-21 04:01PM	Axogen, Inc. Appoints John H. Johnson to Board of Directors (GlobeNewswire)
07:00AM	Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt (Business Wire)
Jul-06-21 07:00AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-21 07:53AM	Have Insiders Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares? (Simply Wall St.)
Jun-24-21 07:00AM	Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors (Business Wire)
Jun-21-21 10:00AM	2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin (Motley Fool)
Jun-13-21 11:03AM	3 Monster Growth Stocks That Could Reach New Highs (TipRanks)
Jun-11-21 06:24AM	Verastem (VSTM) Enters Overbought Territory (Zacks)

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Calkins Daniel	Vice President of Finance	Oct 05	Sale	7.30	5	36	8,432	Oct 10 04:31 PM
Calkins Daniel	Vice President of Finance	Sep 25	Sale	9.40	25	235	8,437	Sep 25 04:46 PM
Calkins Daniel	Vice President of Finance	Sep 21	Sale	9.31	232	2,160	8,462	Sep 25 04:46 PM
Stuglik Brian M	Director	Sep 19	Sale	9.84	274	2,696	91,211	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 19	Sale	9.84	183	1,801	87,343	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 19	Sale	9.84	130	1,279	46,626	Sep 20 04:15 PM
Stuglik Brian M	Director	Sep 18	Sale	9.91	478	4,737	91,485	Sep 20 04:15 PM
Gagnon Robert E.	Director	Sep 18	Sale	9.91	278	2,755	46,756	Sep 20 04:15 PM
Paterson Dan	President and CEO	Sep 18	Sale	9.91	240	2,378	87,526	Sep 20 04:15 PM
Calkins Daniel	Vice President of Finance	Jul 06	Sale	8.02	5	40	8,694	Jul 10 04:05 PM
Calkins Daniel	Vice President of Finance	Jun 26	Sale	8.17	26	212	8,422	Jun 28 04:11 PM
Stuglik Brian M	Chief Executive Officer	Jun 20	Sale	10.30	275	2,832	91,963	Jun 21 04:23 PM
Paterson Dan	President and COO	Jun 20	Sale	10.30	183	1,885	37,766	Jun 21 04:25 PM
Gagnon Robert E.	Director	Jun 20	Sale	10.30	130	1,339	47,034	Jun 21 04:24 PM
Stuglik Brian M	Chief Executive Officer	Jun 16	Sale	9.92	487	4,831	92,238	Jun 21 04:23 PM
Gagnon Robert E.	Director	Jun 16	Sale	9.92	283	2,807	47,164	Jun 21 04:24 PM
Paterson Dan	President and COO	Jun 16	Sale	9.92	244	2,420	37,949	Jun 21 04:25 PM
Calkins Daniel	Vice President of Finance	Apr 05	Sale	0.37	75	28	101,397	Apr 06 04:30 PM
Calkins Daniel	Vice President of Finance	Mar 24	Sale	0.42	378	159	101,472	Mar 28 04:30 PM
Stuglik Brian M	Chief Executive Officer	Mar 20	Sale	0.43	3,508	1,508	1,112,736	Mar 20 04:54 PM
Paterson Dan	President and COO	Mar 20	Sale	0.43	2,339	1,006	458,351	Mar 20 04:57 PM
Gagnon Robert E.	Director	Mar 20	Sale	0.43	1,664	716	569,399	Mar 20 04:59 PM
Stuglik Brian M	Chief Executive Officer	Mar 16	Sale	0.40	6,276	2,510	1,116,244	Mar 20 04:54 PM
Gagnon Robert E.	Director	Mar 16	Sale	0.40	3,654	1,462	571,063	Mar 20 04:59 PM
Paterson Dan	President and COO	Mar 16	Sale	0.40	3,138	1,255	460,690	Mar 20 04:57 PM
Calkins Daniel	Vice President of Finance	Jan 05	Sale	0.43	74	32	98,517	Jan 09 04:06 PM
Calkins Daniel	Vice President of Finance	Dec 27	Sale	0.33	1,246	411	98,591	Dec 29 04:07 PM
Stuglik Brian M	Chief Executive Officer	Dec 19	Sale	0.37	3,556	1,316	1,122,520	Dec 20 04:09 PM
Paterson Dan	President and COO	Dec 19	Sale	0.37	2,954	1,093	463,828	Dec 20 04:10 PM
Gagnon Robert E.	Director	Dec 19	Sale	0.37	1,429	529	574,717	Dec 20 04:09 PM
Stuglik Brian M	Chief Executive Officer	Dec 16	Sale	0.40	25,162	10,065	1,126,076	Dec 20 04:09 PM
Paterson Dan	President and COO	Dec 16	Sale	0.40	15,676	6,270	466,782	Dec 20 04:10 PM
Gagnon Robert E.	Director	Dec 16	Sale	0.40	12,408	4,963	576,146	Dec 20 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VSTM

Verastem Inc

Upgrade your FINVIZ experience